Depletion, Repopulation and Tolerance in Non-Sensitied Recipients
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients
批准号:
9980790
负责人:
Allan D. Kirk
金额:
$97.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-15 至 2022-07-31
关键词:
AcuteAdjuvantAlloantigenAllograftingAnimalsAntigensAntithymoglobulinAttentionAutoimmunityBone MarrowCD28 geneCD80 geneCD8B1 geneCalcineurinCalcineurin inhibitorCell Adhesion MoleculesCell DeathCellsCharacteristicsChimeric ProteinsChimerismChronicClinicalClinical TrialsCytomegalovirusDataDevelopmentElementsExcisionFosteringGraft SurvivalHilarHumanImmuneImmunityImmunosuppressionImpairmentIsoantibodiesKidneyKidney TransplantationKnowledgeLeadLigationLymphaticLymphocyteLymphocyte DepletionMS4A1 geneMacaca mulattaMaintenanceMarrowMediatingMesenchymal Stem CellsMolecularMonoclonal AntibodiesOutputPPP3CA genePathway interactionsPatientsPerioperativePhenotypePopulationPredispositionProcessReceptor SignalingRegimenRegulationReportingResidual stateResistanceRhesusRiskShapesSideSirolimusSpecificitySplenectomySteroidsStimulusT cell differentiationT memory cellT-Cell ReceptorT-LymphocyteTherapeuticTherapeutic immunosuppressionThymectomyThymus GlandTimeViralViral AntigensVirus DiseasesWorkalemtuzumabbaseexperienceinsightirradiationkidney allograftmTOR InhibitormTOR inhibitionnonhuman primatepreventsecondary lymphoid organside effecttherapeutic effectiveness
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – Project 1 (Kirk, Project Lead)
Kidney transplantation's considerable benefit is offset by the many complications associated with chronic
immunosuppressive therapy. Calcineurin inhibitor (CNI)-based regimens are used by over 95% of patients, but
these indiscriminately impair immune processes, including those that facilitate graft acceptance, and produce
significant side effects. Costimulation blockade (CoB), particularly CD28-CD80/86 pathway inhibition, has been
shown to promote long-term allograft survival with fewer side effects than CNIs, and recent clinical trials have
suggested that lymphocyte depletion fosters CoB-based regimens, not only preventing rejection, but fostering
adaptive processes that reduce the needs for immunosuppression with time, and promoting allospecific
tolerance. This project seeks to define the elements of lymphocyte depletion that foster CoB-based
tolerance. We have shown that lymphocyte depletion, and subsequent homeostatic repopulation, present
opportunities to shape the alloreactive immune repertoire to favor tolerance, but also poses risks to disrupt
regulation, and ignite viral infection, autoimmunity and activation of alloreactive clones. Our experimental plan
seeks to understand these two sides of depletional induction. We hypothesize that the effectiveness of
therapeutic lymphocyte depletion is NOT driven by direct elimination of CoB-resistant cells, but rather by
creating a stimulus for lymphocyte turnover and thymic output, fostering antigen-specific activation induced cell
death (AICD). Viewed this way, the approach to depletion changes from cell elimination, to promoting and
managing repopulation, the latter controlled by relative (not absolute), maturation-defined susceptibilities of the
residual lymphocyte population to the effects of antigen exposure, secondary lymphoid organ function, and
immunosuppression. We posit that these factors are tractable, and can be therapeutically manipulated. To
explore this, we propose 3 specific aims: Specific Aim 1: We will define the effects of depletional induction
regimens (broad polyclonal or targeted monoclonal antibody mediated depletion) in rhesus monkeys
undergoing kidney transplantation, comparing the effects of CNIs and mTOR inhibitors on homeostatic
repopulation, and relate these to the efficacy of belatacept-induced tolerance. Specific Aim 2: We will define
the impact of thymic or splenic resection or irradiation on homeostatic repopulation of allospecific cells.
Specific Aim 3: We will define the impact of donor and viral (CMV) antigen exposure on repopulation and
tolerance, providing prolonged donor antigen in the form of bone marrow or mesenchymal stem cells, and
studying these regimens in CMV naïve animals, animals with thymic irradiation. All studies will be heavily
mechanistically supported to assess the phenotype, specificity and function of the repopulating repertoire. We
will partner with Project 2 to define the impact of these maneuvers on alloantibody formation, and matrix the
results in the Project with those of Project 2 to establish a paradigm to guide the development of an optimized
depletional regimen to pair with CoB.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advanced Immunobiology Traning Program for Surgeons
-
批准号:10598547
-
项目类别:
-
资助金额:$25.42万
-
财政年份:2019
-
负责人:Allan D. Kirk
-
依托单位:
Advanced Immunobiology Traning Program for Surgeons
-
批准号:10396460
-
项目类别:
-
资助金额:$26.24万
-
财政年份:2019
-
负责人:Allan D. Kirk
-
依托单位:
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients
-
批准号:10214495
-
项目类别:
-
资助金额:$85.48万
-
财政年份:2017
-
负责人:Allan D. Kirk
-
依托单位:
Computational Immunobiology Core
-
批准号:10622057
-
项目类别:
-
资助金额:$82.76万
-
财政年份:2017
-
负责人:Allan D. Kirk
-
依托单位:
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients
-
批准号:10649945
-
项目类别:
-
资助金额:$65.75万
-
财政年份:2017
-
负责人:Allan D. Kirk
-
依托单位:
Cell Adhesion and Trafficking as a Therapeutic Target in Allotransplantation
-
批准号:8705985
-
项目类别:
-
资助金额:$92.53万
-
财政年份:2014
-
负责人:Allan D. Kirk
-
依托单位:
T Cell Maturation and the Nexus of Viral- and Allo-Immunity
-
批准号:8371823
-
项目类别:
-
资助金额:$52.23万
-
财政年份:2012
-
负责人:Allan D. Kirk
-
依托单位:
T Cell Maturation and the Nexus of Viral- and Allo-Immunity
-
批准号:8463978
-
项目类别:
-
资助金额:$54.87万
-
财政年份:2012
-
负责人:Allan D. Kirk
-
依托单位:
T Cell Maturation and the Nexus of Viral- and Allo-Immunity
-
批准号:8607811
-
项目类别:
-
资助金额:$2.1万
-
财政年份:2012
-
负责人:Allan D. Kirk
-
依托单位:
ADJUVANT THERAPIES IMPROVING ANTI-REJECTION EFFECTS OF COSTIMULATION BLOCKADE
-
批准号:8357527
-
项目类别:
-
资助金额:$3.29万
-
财政年份:2011
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes
-
批准号:8130671
-
项目类别:
-
资助金额:$95.83万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes
-
批准号:8318260
-
项目类别:
-
资助金额:$93.46万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal porcine islet xenografts for the treatment of type 1 diabetes
-
批准号:10640095
-
项目类别:
-
资助金额:$109.09万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Development of Transplant Strategies Uniquely Responsive to the Needs of Children
-
批准号:8138802
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes
-
批准号:7996793
-
项目类别:
-
资助金额:$96.69万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes
-
批准号:8522137
-
项目类别:
-
资助金额:$89.54万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes
-
批准号:8715681
-
项目类别:
-
资助金额:$91.59万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal porcine islet xenografts for the treatment of type 1 diabetes
-
批准号:10434058
-
项目类别:
-
资助金额:$109.09万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
ADJUVANT THERAPIES IMPROVING ANTI-REJECTION EFFECTS OF COSTIMULATION BLOCKADE
-
批准号:8172492
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes
-
批准号:9756295
-
项目类别:
-
资助金额:$93.68万
-
财政年份:2010
-
负责人:Allan D. Kirk
-
依托单位:
海外基金